ReviewFrontiers in medicine2024
Skin barrier-inflammatory pathway is a driver of the psoriasis-atopic dermatitis transition.
Review in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- Inflammatory Aging-Driven Immune Axis Imbalance and the Mechanisms of Chronicity in Elderly Atopic Dermatitis: A Systematic Review and Meta-Analysis.Immunity, inflammation and disease · 2026Pooled it
- Temperature extremes and autoimmune diseases.Seminars in immunopathology · 2026Review
- Drug-induced psoriasis following sacubitril/valsartan: a case report and literature review.BMC cardiovascular disorders · 2026Review
- CLDN7: Epithelial gatekeeper from physiology to pathology‑roles in cancer and epithelial‑related diseases (Review).International journal of molecular medicine · 2026Review
- Sulforaphane in Cutaneous Disorders and Skin Injury: Mechanisms, Evidence, and Clinical Perspectives.Nutrients · 2026Review
- Exploring the Dermatological Benefits of Coffee Extracts and Their Derivatives.Antioxidants (Basel, Switzerland) · 2026Review
- Chaga Mushroom (Journal of microbiology and biotechnology · 2026Article
- Effects of Kiperin Elixea, a multicomponent antioxidant supplement, on redox homeostasis and longevity-associated gene expression in human epithelial cell models.Frontiers in aging · 2026Article
- Skin barrier dysfunction and correlation with the onset and progression of psoriasis.Frontiers in immunology · 2026Review
- Cxcl9 as a Marker of Adipose Tissue Changes Caused by Bariatric Surgery and Psoriasis.Clinical, cosmetic and investigational dermatology · 2026Article
- Aging-associated immune and stromal programs mark interferon- and remodeling-linked spatial contexts in psoriatic skin.Frontiers in immunology · 2026Article
- A Systemic Pathophysiological View of Sensitive Skin Revealed by Proteomics: Beyond Barrier and Inflammation.Journal of cosmetic dermatology · 2026Article
- Luteolin Disrupts Keratinocyte-Dendritic Cell Communication in Psoriasis by Targeting Rh Family C Glycoprotein.Mediators of inflammation · 2026Article
- Article
- Immunological and molecular biomarkers in skin allergy therapy: monitoring inflammation, barrier function, and treatment response.Postepy dermatologii i alergologii · 2026Review
- Unravelling the Mystery of Psoriasis Dermatitis (PsoDermatitis): A Practical Guide to Recognition and Management.Journal of clinical medicine · 2025Review
- Sesamol regulates AQP3 and HAS2 via MAPK signaling for skin barrier protection an in vitro and molecular docking study.Scientific reports · 2025Article
- A novel 2-oxopyrrolidine derivative (LN-53) efficiently induces Nrf-2 signaling pathway activation in human epidermal keratinocytes.Pharmacological reports : PR · 2025Article
- Diagnostic and Therapeutic Challenges in Psoriasis-Atopic Dermatitis Overlap: A Retrospective Observational Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Flavonoids as Natural Anti-Inflammatory Agents in the Atopic Dermatitis Treatment.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As chronic inflammatory conditions driven by immune dysregulation are influenced by genetics and environment factors, psoriasis and atopic dermatitis (AD) have traditionally been considered to be distinct diseases characterized by different T cell responses. Psoriasis, associated with type 17 helper T (Th17)-mediated inflammation, presents as well-defined scaly plaques with minimal pruritus. AD, primarily linked to Th2-mediated inflammation, presents with poorly defined erythema, dry skin, and intense itching. However, psoriasis and AD may overlap or transition into one another spontaneously, independent of biological agent usage. Emerging evidence suggests that defects in skin barrier-related molecules interact with the polarization of T cells, which forms a skin barrier-inflammatory loop with them. This loop contributes to the chronicity of the primary disease or the transition between psoriasis and AD. This review aimed to elucidate the mechanisms underlying skin barrier defects in driving the overlap between psoriasis and AD. In this review, the importance of repairing the skin barrier was underscored, and the significance of tailoring biologic treatments based on individual immune status instead of solely adhering to the treatment guidelines for AD or psoriasis was emphasized.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.